Nicole Casasanta, MD
Clinical FellowAbout
Research
Publications
2024
Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS)
Casasanta N, Patel R, Raymond S, Kier M, Blanter J, Sohval S, Hovstadius M, Wu C, Zimmerman B, Cascetta K, Bagiella E, Tiersten A. Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS). Clinical Breast Cancer 2024, 24: 585-596. PMID: 38971641, DOI: 10.1016/j.clbc.2024.06.005.Peer-Reviewed Original ResearchBreast Cancer IndexEarly-stage breast cancerOncotype DX RSAssociated with discordanceOncotype DX recurrence scoreAdjuvant therapy benefitReview of womenOncotype DXRecurrence scoreRecurrence riskEndocrine therapyCancer indexRetrospective chart review of womenChart review of womenRetrospective review of womenRisk of distant recurrenceTherapy benefitRisk of recurrenceRetrospective chart reviewRegression modelsUnivariate logistic regression modelLogistic regression modelsPrediction scoreDistant recurrenceAdjuvant therapyFactors that impact aromatase inhibitor adherence in early-stage hormone receptor positive breast cancer.
Yang A, Baldwin E, Casasanta N, Tiersten A, Kier M. Factors that impact aromatase inhibitor adherence in early-stage hormone receptor positive breast cancer. Journal Of Clinical Oncology 2024, 42: e12524-e12524. DOI: 10.1200/jco.2024.42.16_suppl.e12524.Peer-Reviewed Original ResearchFirst-line AITherapy useSide effectsRecurrence riskBreast cancerNo significant differenceAromatase inhibitorsEarly-stage hormone receptor-positive breast cancerHormone receptor-positive breast cancerEfficacy of aromatase inhibitorsTreatment due to side effectsReceptor-positive breast cancerAI adherenceEarly-stage breast cancerSocioeconomic demographicsPatients' recurrence riskCohort median agePositive breast cancerSignificant differenceFisher's exact testSide effect frequencyPearson chi-square testKruskal-Wallis rank sum testRank sum testEndocrine treatment
2023
Women with pathogenic variants in moderate penetrance breast cancer genes: How frequently do they meet high penetrance genetic testing criteria?
Casasanta N, Soper E, Abul-Husn N. Women with pathogenic variants in moderate penetrance breast cancer genes: How frequently do they meet high penetrance genetic testing criteria? Journal Of Clinical Oncology 2023, 41: 10584-10584. DOI: 10.1200/jco.2023.41.16_suppl.10584.Peer-Reviewed Original ResearchGenetic testing criteriaNational Comprehensive Cancer Network criteriaNational Comprehensive Cancer NetworkBreast cancer genesClinical genetic testingGenetic testingPersonal historyPenetrance breast cancer genesBreast cancerPersonal history of breast cancerMP geneGenetic riskModerate penetranceBreast cancer predisposition genesCancer genetic testingCancer genesElectronic medical record reviewHigh-penetrance genesPathogenic variantsMedical record reviewGermline pathogenic variantsCancer predisposition genesAssociated with germline pathogenic variantsManagement of individualsComprehensive Cancer NetworkOutcomes with panobinostat in heavily pretreated multiple myeloma patients
Pan D, Mouhieddine T, Upadhyay R, Casasanta N, Lee A, Zubizarreta N, Moshier E, Richter J. Outcomes with panobinostat in heavily pretreated multiple myeloma patients. Seminars In Oncology 2023, 50: 40-48. PMID: 37005144, DOI: 10.1053/j.seminoncol.2023.03.006.Peer-Reviewed Original ResearchConceptsMultiple myelomaStandard-of-care therapyResponse rateTriple-class refractory diseaseHigh-risk cytogeneticsClinical benefit rateMedian overall survivalProgression-free survivalRefractory multiple myelomaMultiple myeloma patientsHistone-deacetylase inhibitorsDescending order of frequencyMount Sinai HospitalOral optionOverall survivalRefractory diseaseMyeloma patientsBenefit ratePanobinostatAcademic medical centerTriple classPatientsMyelomaAgent combinationsSinai Hospital
2022
Outcomes with Panobinostat in Heavily Pretreated Multiple Myeloma Patients
Pan D, Mouhieddine T, Upadhyay R, Casasanta N, Lee A, Zubizarreta N, Moshier E, Richter J. Outcomes with Panobinostat in Heavily Pretreated Multiple Myeloma Patients. Blood 2022, 140: 12483-12484. DOI: 10.1182/blood-2022-159806.Peer-Reviewed Original ResearchPresentation of concurrent thrombotic thrombocytopenic purpura and Graves’ disease
Casasanta N, Shah N, Troy K, Edwards C, Patel R. Presentation of concurrent thrombotic thrombocytopenic purpura and Graves’ disease. Blood Coagulation & Fibrinolysis 2022, 33: 422-424. PMID: 35867945, DOI: 10.1097/mbc.0000000000001154.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraThrombocytopenic purpuraGraves' diseaseAutoimmune diseasesConcurrent thrombotic thrombocytopenic purpuraDeficient activity of ADAMTS13Retrospective review of patientsDiagnosing TTPUncontrolled autoimmune diseaseReview of patientsThyroid function testsAutoimmune thyroid diseaseActivity of ADAMTS13Thrombotic microangiopathyRetrospective reviewThyroid diseaseAutoimmune disordersStandard treatmentFunction testsDeficient activityPatientsThyrotoxicosisPurpuraDiseaseGravesSocioeconomic disparities in supportive therapy use and tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer.
Kier M, Li Z, Casasanta N, Patel R, Agarwal P, Zimmerman B, Yang Y, Fink M, Zhou X, Newman S, Chen R, Schadt E, Oh W, Tiersten A. Socioeconomic disparities in supportive therapy use and tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer. Journal Of Clinical Oncology 2022, 40: 523-523. DOI: 10.1200/jco.2022.40.16_suppl.523.Peer-Reviewed Original ResearchRate of discontinuationSupportive therapyBreast cancerAI therapyDiscontinuation ratesSocioeconomic disparitiesInsurance coverageEarly-stage hormone receptor-positive breast cancerSide effectsExact testHormone receptor-positive breast cancerAdjuvant aromatase inhibitor therapyReceptor-positive breast cancerHormone-positive breast cancerInitial AI therapyAromatase inhibitor therapyRetrospective chart reviewMajority of patientsPositive breast cancerBreast cancer survivalFisher's exact testLow socioeconomic statusAdjuvant AIPrimary languageEarly discontinuation
2019
Response to Letter to the Editor: High Oncotype DX Recurrence Score, Hereditary Cancer Syndromes, and Referral for Germline Genetic Testing
Casasanta N, Amdur R, Kaltman R. Response to Letter to the Editor: High Oncotype DX Recurrence Score, Hereditary Cancer Syndromes, and Referral for Germline Genetic Testing. Clinical Breast Cancer 2019, 20: e198-e199. PMID: 31964593, DOI: 10.1016/j.clbc.2019.12.007.Peer-Reviewed Original ResearchRelationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score
Casasanta N, Kipnis S, Linville L, Lipinski S, Knoedler A, Marino A, McHenry A, Biagi T, Stark E, Amdur R, Denduluri N, Rodriguez P, Isaacs C, Kaltman R. Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score. Clinical Breast Cancer 2019, 20: 125-130. PMID: 31526714, DOI: 10.1016/j.clbc.2019.07.004.Peer-Reviewed Original ResearchConceptsGermline mutation statusOncotype DX recurrence scoreBreast cancer patientsRecurrence scoreMutation statusOncotype DXAssociation of RSGermline mutationsCancer patientsHormone receptor-positive breast cancer patientsHereditary cancer riskGermline genetic testingGenetic risk assessmentHereditary cancer syndromesAssociated with germline mutationsBenefit of chemotherapyRetrospective analysis of dataMultivariate logistic regression modelLikelihood of recurrenceFisher's exact testMultivariate logistic regressionCounseling of family membersLogistic regression modelsNon-BRCA1/2BRCA2 genes
2018
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors
Andricovich J, Perkail S, Kai Y, Casasanta N, Peng W, Tzatsos A. Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors. Cancer Cell 2018, 33: 512-526.e8. PMID: 29533787, PMCID: PMC5854186, DOI: 10.1016/j.ccell.2018.02.003.Peer-Reviewed Original ResearchConceptsPancreatic cancerCOMPASS-like complexesBET inhibitorsMetastatic pancreatic cancerSensitivity to BET inhibitorsSubtypes of tumorsSpectrum of malignanciesPatient-tailored therapySuper-enhancersActivation of super-enhancersSquamous-likeTumor suppressor functionSquamous differentiationRestrained tumor growthTailored therapyTumor growthTherapeutic nicheKDM6A lossSuppressor functionAberrant activationKDM6ACancerCharacterized mechanismsInhibitorsConcomitant loss